Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A growing landscape for sickle cell disease (SCD) treatments, a growing relationship between the companies, and the potential ...
Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results